Myelodysplastic Syndrome (MDS) Treatment Market - Global Industry Insights 2025

Myelodysplastic syndrome (MDS) is a disorder, which affects the bone marrow and produces immature blood cells. Bone marrow failure leads to lowering the levels of healthy blood cells circulation in the bloodstream. According to Seattle Cancer Care Alliance, around 80%-85% of people with MDS have more cells in their bone marrow than healthy people. According to National Organization for Rare Disorders, MDS deteriorates into a form of cancer in around 30% of the patients, known as Acute Myeloid Leukemia (AML). MDS is most commonly found in aging population and remains an incurable disease in majority of patients. According to the American Cancer Society, over 13,000 new cases of MDS occur in the U.S. every year. This is expected to drive the growth of myelodysplastic syndrome treatment market. Hypomethylating drugs such as azacitidine and decitabine help stimulate blood cells to mature and improve blood cell production in MDS.

Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/775

Market Dynamics

According to the American Society of Hematology, in 2016, prevalence of MDS ranged from 0.22-13.2 per 100,000, on all age categories and ethnicities globally. Increasing public awareness about the disease and introduction of new treatment for MDS will drive the growth of the market. Furthermore, growing aging population is analyzed to be a major factor propelling the growth of myelodysplastic syndrome treatment market. According to NCBI, 2012, the incidence of MDS increases significantly with age and the disease is most prevalent in males. Besides, companies such as Celgene and Novartis, who offer innovative brands in this market would be able to combat the loss of share, post patent expiry through their pipeline molecules expected to be launched during the forecast period.

Market Taxonomy

This report segments the global myelodysplastic syndrome treatment market on the basis of drugs. On the basis of drugs, the global Myelodysplastic syndrome treatment market is classified into Azacitidine, Lenalidomide, Decitabine, and Deferasirox. For comprehensive understanding of market dynamics, the global myelodysplastic syndrome treatment market is analyzed across key geographical regions namely North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Browse Research Report At: https://www.coherentmarketinsights.com/market-insight/myelodysplastic-syndrome-treatment-market-775

Key features of the study:

This report provides in-depth analysis of myelodysplastic syndrome treatment and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2017 – 2025), considering 2016 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global myelodysplastic syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
Key companies covered as a part of this study include Novartis AG, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd., Sandoz Inc., Dr Reddys Laboratories Limited, Pharmascience Inc., Accord Healthcare Ltd, Mylan N.V.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion and marketing tactics
The global myelodysplastic syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, Myelodysplastic syndrome treatment manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the myelodysplastic syndrome treatment market

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
Visit Coherent Market Insights Blog @ https://blog.coherentmarketinsights.com/
Connect with us on LinkedIn @ https://www.linkedin.com/company/coherent-market-insights

This release was published on openPR.